Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2013

View Archived Issues

Janssen presents phase III results from QUEST-2 and PROMISE trials of simeprevir

UMC Utrecht Holding divulges new fusion proteins

Shionogi and TB alliance set to collaborate

Allergan advances novel glaucoma compound into preclinical development

Researchers at Variation Biotechnologies patent new vaccines for HCMV infection

First-in-human evaluation of a DNAzyme in adults with nodular basal cell carcinoma

CSL Behring doses first patient in part 3 of global AFFINITY trial program

Researchers from MD Anderson Cancer Center present novel cancer gene therapy

PhaseBio begins first-in-human phase I study of long-acting basal insulin for diabetes

NIH will fund antibacterial resistance research network at Duke University

The Medicines Company enters agreement to acquire ProFibrix

NB Health Laboratory and Mercachem expand partnership

Prolor Biotech begins pivotal phase III trial of hGH-CTP

First-in-human data for vantictumab, an antibody targeting the Wnt pathway

Tunitas Therapeutics receives phase II SBIR grant to advance asthma program

Phase II Pluristem Therapeutics trial to be put on clinical hold

IL-23 receptor modulator peptide shows potential in animal models of arthritis

BTF as a biomarker of severe events in patients with AF

Bayer acquires majority interest in Conceptus

FDA grants fast track designation to NNZ-2566 in Rett syndrome

Almirall patents novel agents for respiratory disorders

The Vanderbilt University discloses new allosteric modulators of the M1 receptor

Novel XIAP inhibitors presented by Bristol-Myers Squibb and Ensemble Therapeutics

Researchers at Allergan design novel FPRL1 ligands

BioMarin commences phase III program for PKU treatment candidate

FDA approves lenalidomide for relapsed/refractory mantle cell lymphoma

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...